Published in

Medknow Publications, Indian Journal of Nephrology, 1(23), p. 71

DOI: 10.4103/0971-4065.107216

Links

Tools

Export citation

Search in Google Scholar

Combined approach with therapeutic drug monitoring and pharmacogenomics in renal transplant recipients

Journal article published in 2013 by Bs S. Mathew, Dh H. Fleming, S. Manvizhi, G. Basu ORCID, Gt T. John
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

In patients undergoing renal transplantation, dose individualization for tacrolimus is routinely achieved with therapeutic drug monitoring (TDM). The patient started on 5.5 mg/day of tacrolimus had a significantly elevated tacrolimus trough concentration. The tacrolimus dose was regularly reduced following TDM at many time periods in the post transplant period but the tacrolimus concentration was consistently elevated. Genomic analysis done after four years revealed mutations in the genes encoding for CYP3A5 and MDR1 (2677G > T). Pharmacogenomics alongside TDM, will soon emerge as the backbone of dose individualization. But for genomics to be beneficial, it should be advocated in the pre-transplant or early post transplant period.